Compare Summit Therapeutics Inc (SMMT) vs STMicroelectronics NV (STM) Price & Performance

Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.

The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.

STM trades at $51.97, down 0.52% today, with a bullish technical signal and support near $52. The company reported mixed Q2 2026 earnings, beating EPS estimates but showing a net income margin of -0.39% in 2026. Recent news highlights AI data-center revenue targets exceeding $2 billion by 2027, driven by optical connectivity and industrial automation, though near-term margins face pressure from fab transitions.

Outlook is cautiously optimistic with a consensus price target of $71.83, implying 38% upside, supported by AI growth catalysts. Risks include earnings volatility, competitive pressures in semiconductors, and macroeconomic headwinds. Analysts are 52% buy-rated, but investors should monitor execution on profitability improvements.